Estrogens, enzyme variants, and breast cancer: A risk model

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 9, 2006, Pages 1620-1629

  Crooke, Philip S ^a   Ritchie, Marylyn D ^b   Hachey, David L ^a   Dawling, Sheila ^a   Roodi, Nady ^a   Parl, Fritz F ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 3 METHOXYESTRADIOL; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRADIOL 1 GLUTATHIONE; 2 HYDROXYESTRADIOL 4 GLUTATHIONE; 2 METHOXYESTRADIOL; 4 HYDROXYESTRADIOL; 4 HYDROXYESTRADIOL 2 GLUTATHIONE; 4 METHOXYESTRADIOL; CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTRADIOL; ESTRADIOL 2,3 QUINONE; ESTRADIOL 3,4 QUINONE; ESTROGEN DERIVATIVE; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE P1; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; COMPUTER MODEL; CONJUGATION; CONTROLLED STUDY; ENZYME KINETICS; ENZYME METABOLISM; ENZYME POLYMORPHISM; ENZYME PURIFICATION; ESTROGEN METABOLISM; FEMALE; GENOMICS; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; STIMULATION; VALIDATION STUDY;

AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; ESTROGENS; FEMALE; HAPLOTYPES; HUMANS; MODELS, THEORETICAL;

EID: 33749320658     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0198     Document Type: Article

References (63)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
2. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
3. Parl FF. Estrogens, estrogen receptor, and breast cancer. Amsterdam: IOS Press; 2000.
4. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
5. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 1996;9:851-9.
6. Akanni A, Abul-Hajj YJ. Estrogen-nucleic acid adducts: reaction of 3,4-estrone-o-quinone radical anion with deoxyribonucleosides. Chem Res Toxicol 1997;10:760-6.
7. Cavalieri EL, Li KM, Balu N, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 2002;23:1071-7.
8. Li KM, Todorovic R, Devanesan P, et al. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 2004;25:289-97.
9. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24:353-6.
10. Li JJ, Li SA. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987;46:1858-63.
11. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7.
12. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
13. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997;94:10937-42.
14. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17β-estradiol hydroxylation catalyzed by human cytochrome P450 1Bl. Proc Natl Acad Sci USA 1996;93:9776-81.
15. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4.
16. Bolton JL, Pisha E, Zhang F, Qiu S. Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 1998;11:1113-27.
17. Liehr JG, Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med 1990;8:415-23.
18. Nutter LM, Wu YY, Ngo EO, Sierra EE, Gutierrez PL, Abul-Hajj YJ. An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem Res Toxicol 1994;7:23-8.
19. Han X, Liehr JG. Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones. Carcinogenesis 1995;16:2571-4.
20. Shibutani S, Takeshita M, Grollman A. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991;349:431-4.
21. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001;20:7945-53.
22. Terashima I, Suzuki N, Shibutani S. Mutagenic properties of estrogen-quinone derived DNA adducts in Simian kidney cells. Biochemistry 2001;40:166-72.
23. Dawling S, Roodi N, Mernaugh RL, Wang XY, Pari FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001;61:6716-22.
24. Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 2002;12:517-28.
25. Strange RC, Spiteri MA, Ramachandran S, Fryer A. Glutathione-S- transferase family of enzymes. Mutat Res 2001;482:21-6.
26. Hachey DL, Dawling S, Roodi N, Parl FF. Sequential action of phase I and II enzymes cytochrome P450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res 2003;63:8492-9.
27. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-9.
28. Ali-Osman F, Akande O, Antoun G, Mao J, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. J Biol Chem 1997;15:10004-12.
29. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000;10:343-53.
30. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EMJ. Specificity of 17β-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119, and 432. Xenobiotica 2001;31:163-76.
31. Dawling S, Hachey DL, Roodi N, Parl FF. In vitro model of mammary estrogen metabolism: structural and kinetic differences in mammary metabolism of catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 2004;17:1258-64.
32. Kalyanaraman B, Sealy RC, Sivarajah K. An electron spin resonance study of osemiquinones formed during the enzymatic and autoxidation of catechol estrogens. J Biol Chem 1984;259:14018-22.
33. Dawling S, Roodi N, Parl FF. Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res 2003;63:3127-32.
34. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-47.
35. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
36. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
37. [Erratum: Cancer Res 1999;59:1388].
38. Liu K, Muse S. PowerMarker: new genetic data analysis software version 3.0. Available from: http://www.powermarker.net.
39. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
40. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53:79-91.
41. Lewis DFV, Gillam EMJ, Everett SA, Shimada T. Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. Chem Biol Interact 2003;145:281-95.
42. Embrechts J, Lemiere F, Van Dongen W, et al. Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry. J Am Soc Mass Spectrom 2003;14:482-91.
43. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A 1996;93:3294-6.
44. Castagnetta LAM, Granata OM, Traina A, et al. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 2002;8:3146-55.
45. Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702.
46. Tabakovic K, Gleason WB, Ojala WH, Abul-Hajj YJ. Oxidative transformation of 2-hydroxyestrone. Stability and reactivity of 2,3-estione quinone and its relationship to estrogen carcinogenicity. Chem Res Toxicol 1996;9:860-5.
47. Tabakovic K, Abul-Hajj YJ. Reaction of lysine with estrone 3,4-o-quinone. Chem Res Toxicol 1994;7:696-701.
48. Iverson SL, Shen L, Anlar N, Bolton JL. Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem Res Toxicol 1996;9:492-9.
49. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996;24:899-905.
50. Spink DC, Spink BC, Cao JQ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998;19:291-8.
51. Weisz J, Fritz-Wolz G, Gestl S, et al. Nuclear localization of catechol-O-methyltransferase in neoplastic and nonneoplastic mammary epithelial cells. Am J Pathol 2000;156:1841-8.
52. Cairns J, Wright C, Cattan AR, et al. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 1992;166:19-25.
53. Kelley MK, Engqvist-Goldstein A, Montali JA, Wheatley JB, Schmidt DE, Jr., Kauvar LM. Variability of glutathione S-transferase isoenzyme patterns in matched normal and cancer human breast tissue. Biochem J 1994;304:843-8.
54. Alpert LC, Schecter RL, Berry DA, et al. Relation of glutathione S-transferase α and μ isoforms to response to therapy in human breast cancer. Clin Cancer Res 1997;3:661-7.
55. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 2000;27:113-24.
56. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-48.
57. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
58. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994;224:893-9.
59. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. "Hormonal" risk factors, "breast tissue age," and the age-incidence of breast cancer. Nature 1983;303:767-70.
60. Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
61. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:557-9.
62. Conney AH. Introduction to drug-metabolizing enzymes: a path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol 2003;43:1-30.
63. Markushin Y, Zhong W, Cavalieri EL, et al. Spectral characterization of catechol estrogen quinone (CEQ)-derived DNA adducts and their identification in human breast tissue extract. Chem Res Toxicol 2003;16:1107-17.